Was just going to post a similar idea.
2nd Qtr was outlined as the time of the most important announcements/developments in Lander's Open Letter:
- End of highly discounted share offerings (previously .025/share or 60%-80% off trading price). This was to end within 1st Qtr (only another week to go)
- 2nd Qtr dCellVax response filing to FDA based on experiments being conducted by Dr. Kesari at John Wayne Cancer Research Center
- Initial filing of a new IND regarding NR2F6 inhibition. (Recent PRs announced the completion of their initial testing with positive results)
And while the open letter didn't list a time frame for HemaXellerate Orphan Drug Status, we expect that announcement at any time.
So we have 3 significant events anticipated in the 2nd Qtr for the ongoing development and increased valuation of the company as well as hoping for other unknown positive developments (whether collaborations, discovering at NCATS, grants from NIH etc.)
It's hard to wait, but the 2nd qtr is going to be very important for whether or not the company continues to move forward.
Also, all the Ichims' incentive share vestiture deadline is June 2016 (3 INDs, 3 CRO relationships etc.)